DPYD Antibody (F-8): sc-376681

DPYD Antibody (F-8) is a mouse monoclonal IgG1 antibody that detects dihydropyrimidine dehydrogenase (DPYD) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DPYD plays a crucial role in the metabolism of pyrimidines, catalyzing the first rate-limiting step in the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine. This enzymatic activity is vital as a deficiency in DPYD can lead to the accumulation of uracil and thymine, which has been associated with neurological diseases and can complicate cancer treatment, particularly with the use of pyrimidine analogs like 5-fluorouracil (5-FU). Furthermore, variations in DPYD expression, often due to hypermethylation of its promoter, can significantly impact the efficacy and toxicity of 5-FU, making DPYD essential for understanding patient responses to chemotherapy. Anti-DPYD antibody (F-8) is an invaluable tool for researchers investigating the metabolic pathways involving pyrimidines and their implications in both neurological disorders and cancer therapy.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DPYD Antibody (F-8) References:

1. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.  |  Ezzeldin, HH., et al. 2005. Clin Cancer Res. 11: 8699-705. PMID: 16361556
2. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.  |  Kleibl, Z., et al. 2009. Neoplasma. 56: 303-16. PMID: 19473056
3. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.  |  Falvella, FS., et al. 2015. Int J Mol Sci. 16: 8884-95. PMID: 25906475
4. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.  |  Saif, MW. and Diasio, RB. 2016. Cancer Chemother Pharmacol. 78: 151-6. PMID: 27278667
5. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs.  |  Sharma, V., et al. 2019. Cancer Chemother Pharmacol. 84: 1157-1166. PMID: 31482228
6. Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.  |  Malier, M., et al. 2021. Cancer Res. 81: 5963-5976. PMID: 34645611
7. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.  |  de With, M., et al. 2023. ESMO Open. 8: 101197. PMID: 36989883
8. Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD).  |  Zhang, T., et al. 2024. Elife. 13: PMID: 38686795
9. Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities.  |  De Mattia, E., et al. 2024. Int J Biol Sci. 20: 3742-3759. PMID: 39113696
10. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.  |  Diasio, RB. and Lu, Z. 1994. J Clin Oncol. 12: 2239-42. PMID: 7964937

The preferred DPYD antibody is DPYD Antibody (A-5): sc-376712.